What is IMA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.05B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for IMA?

P/E (TTM) is n/a and 52-week range is $3.90 to $9.10 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s IMA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for IMA?

The company profile lists revenue (TTM) near $9M, net income (TTM) near -$6.82B, EPS (TTM) near -$5.34 when available from the market-data feed. Figures are informational and may lag live markets.

Where is ImageneBio Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 11.3M shares outstanding, ISIN US45175G2075 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

ImageneBio Inc

$IMA

Health Care · Biotechnology

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. The company is headquartered in San Diego, California and currently employs 18 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The firm develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The firm is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.

Employees

Website

imagenebio.com

IPO

2021-03-26

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US45175G2075

Headquarters

San Diego, California, US

Shares outstanding

11.3M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

46.48%

Browse other companiesFree AI scores and summaries for more stocks